Liquet Versus New Catheter Configuration Cleared for Pulmonary Artery Pressure Measurement

February 24, 2026—Liquet Medical Inc. announced it has received a second FDA 510(k) clearance for a new configuration of its Versus catheter. The technology enables a physiology-guided approach that the company calls “hemodynamics-led thrombolysis.”

The Versus catheter is intended to provide real-time pulmonary artery (PA) pressure measurements in the treatment of pulmonary embolism (PE). The new configuration expands adoption of the device across specialties, advised the company.

According to Liquet, the new configuration provides enhanced torque control and compatibility with thicker guidewires to meet interventional radiology workflow preferences.

Additionally, the device provides physicians with live data to assess patient hemodynamics before and during therapy. Its dual-tip telescoping design enables simultaneous treatment of both lungs with a single device, allowing access site alternatives, noted the press release.

Liquet Medical stated that it plans to conduct a United States trial for the treatment of PE under an investigational device exemption.

In December 2024, the company announced the first FDA clearance for the Versus device.

Patrick Kelly, MD, a vascular surgeon with Dakota Vascular in Sioux Falls, South Dakota, is the inventor of the Versus catheter and a member of Liquet Medical’s Scientific Advisory Board.

“Current catheter-directed lytic therapy is like driving at night without headlights—you’re making important decisions without full visibility,” commented Dr. Kelly in the company’s press release. “Incorporating real-time PA pressure data provides objective physiologic feedback, which can help physicians better understand patient response and has the potential to optimize therapy decisions.”